与ALK抑制剂和风险因素相关的间歇性肺病:更新的比较药监测分析
Junli Dong1,2, Lulu Li1,2, Tiying Deng1,2
1Department of Pharmacy, Traditional Chinese and Western Medicine Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
无细胞淋巴瘤激酶 (ALK) 氨酸激酶抑制剂 (TKIs) 可以导致间歇性肺病 (ILD),通常在两个月内. 将ALK TKIs与PPI,安洛迪平或氧化结合起来会增加ILD风险.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 肺部病理学 肺部病理学
背景情况:
- 无塑性淋巴瘤激酶 (ALK) 基因突变驱动肺癌,ALK 抑制剂作为一线治疗.
- 美国食品和药物管理局 (FDA) 的标签警告说,使用ALK氨酸激酶抑制剂 (TKIs) 的间歇性肺病 (ILD) 风险.
- 与ALK TKI相关的ILD的特征和风险因素仍然不完全理解.
研究的目的:
- 描述与ALK TKI相关的ILD的临床特征.
- 确定导致ALK TKI相关ILD的独立风险因素.
- 在瘤学中为ALK TKIs提供药监和安全处方实践的信息.
主要方法:
- 提取了FDA不良事件报告系统 (FAERS) 从2011年第一季度到2023年第二季度的数据.
- 利用标准化MedDRA查询 (SMQs) 来识别与ILD相关的不良事件 (AE).
- 采用信号检测算法和后勤回归来分析与ALK TKI相关的ILD风险.
主要成果:
- 分析了20064份ALK TKI报告,确定了640 (3.2%) 的ILD相关的AE.
- 在所有五个评估的ALK TKIs中检测到ILD的显著不成比例;肺炎是常见的毒性.
- 在ILD发病的中位时间为53天,超过70%发生在两个月内;同时使用PPI,安洛迪平和氧化增加了ILD风险.
结论:
- ALK TKIs表现出不同的肺毒性概况,通常在治疗的前两个月内表现出来.
- 同时使用ALK TKIs与质子抑制剂 (PPI),安洛迪平或氧化,可显著增加ILD风险.
- 这些发现为ALK TKI相关的ILD提供了风险预测模型,支持在癌症治疗中加强药物监测.
更多相关视频
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
相关概念视频
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Factors Influencing Drug Absorption: Disease States and Pharmacology
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
Therapeutic Drug Monitoring: Affecting Factors
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Drug Toxicity: Risk factors
